Praxis precision medicines reports positive results of prax-628 study evaluating photo paroxysmal response (ppr) achieving 100% response in treated patients

In the 45 mg cohort, 100% of patients achieved a complete response in the 15 mg cohort, 80% of patients achieved a complete response and 20% achieved a partial response safety was consistent with prior dose escalation study and pk analysis confirmed therapeutic exposures praxis plans to initiate an efficacy study in focal onset epilepsy in the second half of 2024 boston, march 26, 2024 (globe newswire) -- praxis precision medicines , inc. (nasdaq: prax), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (cns) disorders characterized by neuronal excitation-inhibition imbalance, today provided an update on its phase 2a proof of concept study evaluating prax-628 in epilepsy patients with ppr. ppr studies measure electroencephalogram (eeg) signatures after intermittent photic stimulation and are used as an indicator of anti-seizure efficacy.
PRAX Ratings Summary
PRAX Quant Ranking